Tconway, Yes, the NIH trial is supposed (or was
Post# of 154119
(Total Views: 579)
Posted On: 05/20/2020 9:00:00 PM
Re: tconway1118 #34788
Tconway,
Yes, the NIH trial is supposed (or was) to be blinded with placebo.
Therefore my point. NIH is Fauci's baby. They change the endpoint mid-way, and then he announces in the oval office:
Some interesting interview (not sure if has been referenced already that discusses the GILD trial and lack of data:
https://www.msn.com/en-us/money/watch/why-thi...p-BB14ns42
I agree with you, We can expect much better results with leronlimab. However I have serious doubts about the "blindness" of the "placebo control" in the NIH sponsored trial.
The above is not intended to be a political opinion at all (better to keep it out of te equation), I just can't understand how all this has happened and the end result (this was a P2 trial, the drug has not been approved) which is that the drug is being used all over the place.
Yes, the NIH trial is supposed (or was) to be blinded with placebo.
Therefore my point. NIH is Fauci's baby. They change the endpoint mid-way, and then he announces in the oval office:
Quote:
Sitting on a couch in the White House, mostly speaking extemporaneously, with the Scientist-in-Chief sitting a few feet away waiting to hear what he wanted to hear from Dr. Fauci – this is far less than the ideal environment for the delivery of what was described as “quite good news.”
Quote:
Fauci emphasized that the study’s primary endpoint was time to recovery. He called it “highly significant….A 31 percent improvement doesn’t seem like a knockout 100 percent, but it is very important proof of concept.”
Quote:
Some have suggested that his comments represent a conflicted double standard; he used his White House platform to praise his agency’s sponsored study (not published nor peer-reviewed), while slamming a peer-reviewed and published Chinese study.
Quote:
… but noticeably few in mainstream news media – have pointed to the fact that primary endpoints or outcomes were shifted by the researchers in the NIH trial just within the past two weeks. Fauci didn’t acknowledge that in his upbeat pronouncement at the White House. He said that the study’s primary endpoint was time to recovery. Yes, that has been the primary endpoint for the last two weeks. But not before that. The trial started February 21.
Some interesting interview (not sure if has been referenced already that discusses the GILD trial and lack of data:
https://www.msn.com/en-us/money/watch/why-thi...p-BB14ns42
I agree with you, We can expect much better results with leronlimab. However I have serious doubts about the "blindness" of the "placebo control" in the NIH sponsored trial.
The above is not intended to be a political opinion at all (better to keep it out of te equation), I just can't understand how all this has happened and the end result (this was a P2 trial, the drug has not been approved) which is that the drug is being used all over the place.
(4)
(0)